Scholarlink

<p>Pritelivir is a novel anti-herpes simplex virus drug that is currently in clinical trials in nonpregnant immunocompromised subjects. Here we conducted a preliminary embryo-fetal developmental toxicity study of pritelivir in CD1-IGS mice. Pritelivir was administered by oral gavage to time-mated mice at dose levels of 0, 10, 60 and 200&#xa0;mg/kg/day from gestational day 6 through 15. Maternal food consumption, body weight and clinical observations were monitored throughout gestation. The mice were sacrificed at gestational day 18 and assessed based on embryo-fetal development and viability. Fetuses were weighed and examined for external and visceral variations and malformations. The results showed that exposure to pritelivir did not cause maternal or developmental toxicity in mice. Thus, both maternal and fetal no-observed-adverse-effect-level of pritelivir was determined to be 200&#xa0;mg/kg/day. At this dose, the area under the concentration-time curve for pritelivir at steady state in maternal animals was 20 times greater than reported in humans at the clinical dose of 100&#xa0;mg/day. Placenta-to-maternal plasma and fetus-to-maternal plasma concentration ratios in mice were 0.4 and 0.2, respectively, indicating transfer but not accumulation of pritelivir in the fetoplacental compartment. Taken together, our findings support further preclinical studies of pritelivir for its use in pregnancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preliminary embryo-fetal developmental toxicity study of pritelivir in CD1-IGS mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月21日

查看全文
  • Tatiana N. Nanovskaya,
  • Svetlana L. Patrikeeva,
  • Xiaoming Wang,
  • Erik Rytting,
  • Bandana Bera,
  • Sydni C. Zacharias,
  • Brendan Prideaux,
  • Valentina F. Bryant

摘要

Pritelivir is a novel anti-herpes simplex virus drug that is currently in clinical trials in nonpregnant immunocompromised subjects. Here we conducted a preliminary embryo-fetal developmental toxicity study of pritelivir in CD1-IGS mice. Pritelivir was administered by oral gavage to time-mated mice at dose levels of 0, 10, 60 and 200 mg/kg/day from gestational day 6 through 15. Maternal food consumption, body weight and clinical observations were monitored throughout gestation. The mice were sacrificed at gestational day 18 and assessed based on embryo-fetal development and viability. Fetuses were weighed and examined for external and visceral variations and malformations. The results showed that exposure to pritelivir did not cause maternal or developmental toxicity in mice. Thus, both maternal and fetal no-observed-adverse-effect-level of pritelivir was determined to be 200 mg/kg/day. At this dose, the area under the concentration-time curve for pritelivir at steady state in maternal animals was 20 times greater than reported in humans at the clinical dose of 100 mg/day. Placenta-to-maternal plasma and fetus-to-maternal plasma concentration ratios in mice were 0.4 and 0.2, respectively, indicating transfer but not accumulation of pritelivir in the fetoplacental compartment. Taken together, our findings support further preclinical studies of pritelivir for its use in pregnancy.